misleading statements

BellRing Brands faces securities lawsuit alleging false statements about financial performance and growth. Class action covers November 2024 through August 2025 for affected investors.

Ramaco Resources faces securities litigation over alleged misrepresentations regarding Brook Mine operations. Investors who purchased stock during July-October 2025 should consult legal counsel about joining the class action.

Ultragenyx faces securities lawsuit alleging false claims about drug setrusumab for bone disease. Investors have until April 6, 2026 deadline to join class action.

Ultragenyx faces class action lawsuit for allegedly misleading investors about setrusumab efficacy and failing to disclose Phase III trial risks adequately.

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.

Oracle faces securities lawsuit for allegedly misrepresenting AI infrastructure investment returns and failing to disclose significant financial obligations and project delays.

REGENXBIO faces class action lawsuit alleging false statements about RGX-111 gene therapy trial results, covering securities purchased between February 2022 and January 2026.

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors who purchased shares between June 2023 and December 2025 may be eligible.

Mereo BioPharma faces securities lawsuit for allegedly making false statements about setrusumab trial results, causing artificially inflated stock prices and investor losses.

PomDoctor Ltd. faces securities lawsuit alleging false statements, social media manipulation, and insider selling. Investors who bought stock October-December 2025 must act before April 7, 2026 deadline.

BellRing Brands faces securities fraud investigation for allegedly misrepresenting 2025 sales growth, attributing gains to retail inventory buildup rather than organic demand. Stock fell 33%.

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.

Rosen Law Firm sues Sallie Mae for false disclosures on loan delinquencies. Investors have until February 17, 2026 deadline to join the class action lawsuit.

Rosen Law Firm sues Ultragenyx for securities fraud, alleging executives misrepresented drug efficacy. Investors who bought stock August 2023-December 2025 can claim damages by April 6, 2026 deadline.

Klarna faces securities lawsuit alleging it concealed loss reserve increases in its September 2025 IPO. Investors have until February 20 to join the class action.

Class action lawsuit filed against Fermi Inc. alleging material misrepresentations in October 2025 IPO regarding Project Matador demand and financial viability disclosures.

Ultragenyx Pharmaceutical faces class action lawsuit for allegedly making false statements about setrusumab drug efficacy and safety, affecting investors who bought securities between August 2023 and December 2025.

uniQure faces securities lawsuit alleging misleading statements about AMT-130's FDA pathway. Stock dropped 49% after FDA reversed stance. Investors have April deadline for lead plaintiff claims.

Law firm sues Oracle for allegedly misleading investors about AI spending's near-term revenue potential. Stock fell 11% after earnings missed expectations.

Vistagen faces securities class action over alleged misleading statements about drug fasedienol. Investors who purchased stock April 2024-December 2025 can join by March 16, 2026 deadline.